756 related articles for article (PubMed ID: 25476811)
21. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
22. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.
Gurbuz AS; Gode F; Ozcimen N; Isik AZ
Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114
[TBL] [Abstract][Full Text] [Related]
23. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
Dosouto C; Haahr T; Humaidan P
Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
[TBL] [Abstract][Full Text] [Related]
24. Ovarian stimulation for freeze-all IVF cycles: a systematic review.
Mizrachi Y; Horowitz E; Farhi J; Raziel A; Weissman A
Hum Reprod Update; 2020 Jan; 26(1):118-135. PubMed ID: 31867625
[TBL] [Abstract][Full Text] [Related]
25. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
26. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
Radesic B; Tremellen K
Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
Kol S; Itskovitz-Eldor J
Semin Reprod Med; 2010 Nov; 28(6):500-5. PubMed ID: 21082509
[TBL] [Abstract][Full Text] [Related]
28. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
29. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
30. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
[TBL] [Abstract][Full Text] [Related]
31. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
[TBL] [Abstract][Full Text] [Related]
32. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.
Christ J; Herndon CN; Yu B
J Assist Reprod Genet; 2021 Mar; 38(3):751-756. PubMed ID: 33471229
[TBL] [Abstract][Full Text] [Related]
33. Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders.
Ding LJ; Wang B; Shen XY; Yan GJ; Zhang NY; Hu YL; Sun HX
Reprod Biomed Online; 2013 Aug; 27(2):131-9. PubMed ID: 23764202
[TBL] [Abstract][Full Text] [Related]
34. Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.
Orvieto R; Rabinson J; Meltzer S; Zohav E; Anteby E; Homburg R
Reprod Biomed Online; 2006 Aug; 13(2):198-201. PubMed ID: 16895632
[TBL] [Abstract][Full Text] [Related]
35. Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?
Davenport MJ; Vollenhoven B; Talmor AJ
Obstet Gynecol Surv; 2017 May; 72(5):296-308. PubMed ID: 28558117
[TBL] [Abstract][Full Text] [Related]
36. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
[TBL] [Abstract][Full Text] [Related]
37. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
38. Introduction: Gonadotropin-releasing hormone agonist triggering of final follicular maturation for in vitro fertilization.
Casper RF
Fertil Steril; 2015 Apr; 103(4):865-6. PubMed ID: 25681856
[TBL] [Abstract][Full Text] [Related]
39. New algorithm for OHSS prevention.
Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
[TBL] [Abstract][Full Text] [Related]
40. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos.
Garcia-Velasco JA
Fertil Steril; 2012 Mar; 97(3):527-8. PubMed ID: 22222191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
